Open an account

Neumora Therapeutics

NMRA · NASDAQ

$0.465−$0.005 (−1.06%)TodayMarket closed ·
Prev close $0.47

About NMRA

Neumora Therapeutics, Inc. is a clinical-stage biotechnology company. The company is headquartered in Watertown, Massachusetts and currently employs 96 full-time employees. The company went IPO on 2023-09-15. The firm's therapeutic pipeline consists of seven clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. Its advanced product candidate, navacaprant (NMRA-140), is a novel once-daily oral kappa opioid receptor (KOR) antagonist that is being developed for the treatment of depressive disorder (MDD). Navacaprant is being investigated in the KOASTAL pivotal Phase 3 program, evaluating navacaprant monotherapy in patients with moderate to severe MDD. The firm's next advanced product candidate is NMRA-511, which is a highly selective, novel antagonist of the vasopressin 1a receptor (V1aR) being developed for the treatment of agitation associated with dementia due to Alzheimer's disease (AD).

Employees
96
Headquarters
Watertown, Massachusetts
Listed
Sep 15, 2023
Sector
Health Care
Industry
Pharmaceuticals
Website
neumoratx.com

NMRA key statistics

Market cap
87.37M
Price-earnings ratio
0.00
Dividend yield
—
Average volume
2.30M
Volume
974.55K
Open price
$0.48
High today
$0.4963
Low today
$0.4574
52 Week high
$3.65
52 Week low
$0.3154

Neumora Therapeutics (NMRA) at a glance

As of Oct 20, 2026, Neumora Therapeutics (NMRA) shares are priced at $0.465, giving the company a market cap of 87.37M and a price-to-earnings ratio of 0.00.

Today the stock has traded between $0.4574 and $0.4963. The current price is 1.7% above the day's low and 6.3% below its high.

Volume so far is 974.55K shares, below the average of 2.30M shares a day.

Over the past year Neumora Therapeutics has ranged from $0.3154 to $3.65, and now sits 4% of the way up that range.

Neumora Therapeutics met or beat analyst EPS estimates in 5 of the last 8 quarters. In Q2 FY26 it reported -$0.23 per share against an estimate of -$0.2448.

The average analyst price target is $6.27, 1247.5% above the current price, from 8 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

88%of 8 analyst ratings say Buy
  • Buy87.5%
  • Hold12.5%
  • Sell0.0%
Price target · 9 analystsAvg $6.27
Low
$3.03
Now
$0.465
High
$14.70

NMRA earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 5 of the last 8 quarters, by 9.6% on average.

  1. Q3 FY24: reported -$0.45 per share against an estimate of -$0.3978
  2. Q4 FY24: reported -$0.37 per share against an estimate of -$0.4552
  3. Q1 FY25: reported -$0.42 per share against an estimate of -$0.3818
  4. Q2 FY25: reported -$0.33 per share against an estimate of -$0.3757
  5. Q3 FY25: reported -$0.32 per share against an estimate of -$0.3404
  6. Q4 FY25: reported -$0.35 per share against an estimate of -$0.3321
  7. Q1 FY26: reported -$0.30 per share against an estimate of -$0.3162
  8. Q2 FY26: reported -$0.23 per share against an estimate of -$0.2448

NMRA news

  • Vandana Singh

    Why Is BioAge Labs Stock Sinking Friday?

  • Press releaseBusiness Wire

    NMRA Investor Alert: Levi & Korsinsky Investigates Neumora Therapeutics (NMRA) for Potential Securities Fraud

  • Press releasePRNewswire

    NMRA SHAREHOLDER INVESTIGATION: SueWallSt Investigates Neumora Therapeutics for Possible Securities Law Violations

  • Press releasePRNewswire

    Neumora Therapeutics Investigation Initiated: Levi & Korsinsky Investigates the Officers and Directors of Neumora Therapeutics (NMRA)

  • Vandana Singh

    Penny Stock Neumora Therapeutics Cuts Workforce After Depression Trials Fail

  • Press releaseGlobe Newswire

    NMRA INVESTOR ALERT: Holzer & Holzer, LLC Investigation of Neumora Therapeutics, Inc.

  • Avi Kapoor

    Crude Oil Tumbles Over 5%; Empire State Manufacturing Index Falls In June

  • Avi Kapoor

    Dow Jumps Over 600 Points Following US-Iran Peace Deal

Similar companies

Companies in the same industry as Neumora Therapeutics

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.